KDS2010, identified by its CAS number 1894207-45-4, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, physical properties, and biological activity may vary, compounds like KDS2010 are typically evaluated for their solubility, stability, and reactivity under various conditions. It may exhibit specific interactions with biological targets, which can be crucial for its efficacy in drug development. Additionally, safety profiles, including toxicity and environmental impact, are essential considerations in its characterization. As research progresses, detailed studies on its pharmacokinetics and pharmacodynamics will provide further insights into its potential uses and mechanisms of action. For precise information regarding its characteristics, including empirical formulas and specific applications, consulting scientific literature or databases dedicated to chemical substances is recommended.

KDS2010 is a potent, highly selective, and reversible MAO-B inhibitor which shows 12,500-fold selectivity over MAO-A. KDS2010 overcomes the disadvantages of the irreversible MAO-B inhibitor and significantly attenuates increased astrocytic GABA levels and astrogliosis, thereby enhancing synaptic transmission, and rescuing learning and memory impairments in APP/PS1 mice.

KDS2010

1894207-45-4: KDS2010, identified by its CAS number 1894207-45-4, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, physical properties, and biological activity may vary, compounds like KDS2010 are typically evaluated for their solubility, stability, and reactivity under various conditions. It may exhibit specific interactions with biological targets, which can be crucial for its efficacy in drug development. Additionally, safety profiles, including toxicity and environmental impact, are essential considerations in its characterization. As research progresses, detailed studies on its pharmacokinetics and pharmacodynamics will provide further insights into its potential uses and mechanisms of action. For precise information regarding its characteristics, including empirical formulas and specific applications, consulting scientific literature or databases dedicated to chemical substances is recommended.

<p>KDS2010 is a neuroprotective drug that has been shown to reduce the progression of Parkinson's disease and Alzheimer's disease in clinical trials. It is a potent GABA receptor agonist that produces a rapid, reversible increase in intracellular levels of gamma-aminobutyric acid (GABA) by binding to the GABA receptor and inhibiting its ion channel activity. KDS2010 also stimulates the release of dopamine, which may be responsible for its therapeutic effects. KDS2010 is an attenuating agent that reduces neuronal death by attenuating reactive oxygen species generation and preventing the depletion of glutathione.</p>

<p>KDS2010: potent, reversible MAO-B inhibitor with 12,500x selectivity vs. MAO-A; enhances memory in APP/PS1 mice.</p>

CAS 1894207-45-4

KDS2010

KDS2010

Ref: 3D-UAD20745

KDS2010 mesylate

Ref: TM-T70075